Invion Stock

Invion Operating Cash Flow

The Operating Cash Flow of Invion (IVX.AX) as of Sep 3, 2026 is -2.97 M AUD. In the previous year, Operating Cash Flow was -2.40 M AUD — a change of 23.63% (lower).

Operating Cash Flow

-2.97 MAUD

YoY

23.63%

Last updated:

Operating Cash Flow of Invion is 2026 -2.97 M AUD. Operating Cash Flow of Invion was 2025 -2.40 M AUD. It decreases by 23.63% lower compared to the previous year.

The Invion Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
707,100.00 AUD
Jan 1, 2019
-2.11 M AUD
Jan 1, 2020
-152,500.00 AUD
Jan 1, 2021
418,000.00 AUD
Jan 1, 2022
-1.11 M AUD
Jan 1, 2023
-1.81 M AUD
Jan 1, 2024
-2.40 M AUD
Jan 1, 2025
-2.97 M AUD
The Invion Operating Cash Flow history
YEAROperating Cash FlowYoY
-2.97 MAUD+23.63%
-2.40 MAUD+32.48%
-1.81 MAUD+63.47%
-1.11 MAUD-365.29%
418,000.00AUD-374.10%
-152,500.00AUD-92.76%
-2.11 MAUD-397.79%
707,100.00AUD-386.16%
-247,100.00AUD-93.55%
-3.83 MAUD-62.17%
-10.13 MAUD+132.90%
-4.35 MAUD
Access this data via the Eulerpool API

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Operating Cash Flow of Invion is -2.97 M AUD in 2026.

Operating Cash Flow of Invion changed from -2.40 M AUD to -2.97 M AUD, representing a 23.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Invion since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Invion historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Invion

All Key Metrics — Invion